Ocaliva
PreclinicalSmall molecule
Ocaliva is one of 32 small molecule programs targeting Primary Biliary Cholangitis. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
41 competitors in Primary Biliary Cholangitis
#DrugCompanyPhaseTrials
1Cellcept
RocheApproved
Ocaliva
IIntercept Pharmaceuticals
Approved
Cyclosporin a
NovartisApproved
Iqirvo
IpsenPhase 3
Lipaglyn
ZZydus Therapeutics Inc.
Phase 3
Rayos
RRoxane Laboratories
Phase 3
Olumiant
Eli LillyPhase 2
Seladelpar
GileadPhase 3
Bezafibrate
IIntercept Pharmaceuticals
Phase 3
Selincro
IIndivior Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ocaliva. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details